225 related articles for article (PubMed ID: 22134626)
1. Renal phosphate loss in long-term kidney transplantation.
Sirilak S; Chatsrisak K; Ingsathit A; Kantachuvesiri S; Sumethkul V; Stitchantrakul W; Radinahamed P; Disthabanchong S
Clin J Am Soc Nephrol; 2012 Feb; 7(2):323-31. PubMed ID: 22134626
[TBL] [Abstract][Full Text] [Related]
2. Hyperparathyroidism and increased fractional excretion of phosphate predict allograft loss in long-term kidney transplant recipients.
Prakobsuk S; Sirilak S; Vipattawat K; Taweesedt PT; Sumethkul V; Kantachuvesiri S; Disthabanchong S
Clin Exp Nephrol; 2017 Oct; 21(5):926-931. PubMed ID: 27981393
[TBL] [Abstract][Full Text] [Related]
3. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
[TBL] [Abstract][Full Text] [Related]
4. Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.
Sánchez Fructuoso AI; Maestro ML; Pérez-Flores I; Valero R; Rafael S; Veganzones S; Calvo N; De la Orden V; De la Flor JC; Valga F; Vidaurreta M; Fernández-Pérez C; Barrientos A
Nephrol Dial Transplant; 2012 Nov; 27(11):4227-35. PubMed ID: 23144073
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism.
Evenepoel P; Meijers B; Viaene L; Bammens B; Claes K; Kuypers D; Vanderschueren D; Vanrenterghem Y
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1268-76. PubMed ID: 20448073
[TBL] [Abstract][Full Text] [Related]
6. Serum phosphate levels modify the impact of parathyroid hormone levels on renal outcomes in kidney transplant recipients.
Doi Y; Hamano T; Ichimaru N; Tomida K; Obi Y; Fujii N; Yamaguchi S; Oka T; Sakaguchi Y; Matsui I; Kaimori JY; Abe T; Imamura R; Takahara S; Tsubakihara Y; Nonomura N; Isaka Y
Sci Rep; 2020 Aug; 10(1):13766. PubMed ID: 32792668
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid Hormone, Fibroblast Growth Factor 23, and Parameters of Phosphate Reabsorption.
Phelps KR; Mason DL
Am J Nephrol; 2018; 47(5):343-351. PubMed ID: 29779023
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
Dhayat NA; Ackermann D; Pruijm M; Ponte B; Ehret G; Guessous I; Leichtle AB; Paccaud F; Mohaupt M; Fiedler GM; Devuyst O; Pechère-Bertschi A; Burnier M; Martin PY; Bochud M; Vogt B; Fuster DG
Kidney Int; 2016 Sep; 90(3):648-57. PubMed ID: 27370409
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss.
Kanaan N; Claes K; Devogelaer JP; Vanderschueren D; Depresseux G; Goffin E; Evenepoel P
Clin J Am Soc Nephrol; 2010 Oct; 5(10):1887-92. PubMed ID: 20634326
[TBL] [Abstract][Full Text] [Related]
10. Recovery of hyperphosphatoninism and renal phosphorus wasting one year after successful renal transplantation.
Evenepoel P; Meijers BK; de Jonge H; Naesens M; Bammens B; Claes K; Kuypers D; Vanrenterghem Y
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1829-36. PubMed ID: 18922992
[TBL] [Abstract][Full Text] [Related]
11. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?
Wesseling-Perry K; Tsai EW; Ettenger RB; Jüppner H; Salusky IB
Nephrol Dial Transplant; 2011 Nov; 26(11):3779-84. PubMed ID: 21441401
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
Malhotra R; Katz R; Hoofnagle A; Bostom A; Rifkin DE; Mcbride R; Probstfield J; Block G; Ix JH
Clin J Am Soc Nephrol; 2018 Jan; 13(1):36-44. PubMed ID: 29208626
[TBL] [Abstract][Full Text] [Related]
13. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate.
Pavik I; Jaeger P; Kistler AD; Poster D; Krauer F; Cavelti-Weder C; Rentsch KM; Wüthrich RP; Serra AL
Kidney Int; 2011 Jan; 79(2):234-40. PubMed ID: 20944552
[TBL] [Abstract][Full Text] [Related]
14. Effects of cinacalcet in renal transplant patients with hyperparathyroidism.
Courbebaisse M; Diet C; Timsit MO; Mamzer MF; Thervet E; Noel LH; Legendre C; Friedlander G; Martinez F; Prié D
Am J Nephrol; 2012; 35(4):341-8. PubMed ID: 22473131
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23, but not parathyroid hormone, is associated with urinary phosphate regulation in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Tokumoto M; Yoshida H; Hasegawa S; Tanaka S; Eriguchi M; Nakano T; Masutani K; Ooboshi H; Kitazono T
Ther Apher Dial; 2015 Feb; 19(1):73-80. PubMed ID: 25195562
[TBL] [Abstract][Full Text] [Related]
16. The effects of mineral metabolism markers on renal transplant outcomes.
Marcén R; Jimenez S; Fernández A; Galeano C; Villafruela JJ; Burgos FJ; Quereda C
Transplant Proc; 2012 Nov; 44(9):2567-9. PubMed ID: 23146456
[TBL] [Abstract][Full Text] [Related]
17. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.
Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
Nephrol Dial Transplant; 2011 Aug; 26(8):2691-5. PubMed ID: 21303965
[TBL] [Abstract][Full Text] [Related]
18. Renal Clearance of Mineral Metabolism Biomarkers.
van Ballegooijen AJ; Rhee EP; Elmariah S; de Boer IH; Kestenbaum B
J Am Soc Nephrol; 2016 Feb; 27(2):392-7. PubMed ID: 26047790
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients.
Krajisnik T; Olauson H; Mirza MA; Hellman P; Akerström G; Westin G; Larsson TE; Björklund P
Kidney Int; 2010 Nov; 78(10):1024-32. PubMed ID: 20686451
[TBL] [Abstract][Full Text] [Related]
20. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
